MicroPort Scientific (0853) AI Stock Analysis

• Market Cap: HK$15.91B
• Dividend Yield: N/A
• Average Volume (3M): 25.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: 8.11%
• EPS Growth: 55.55%
• Country: HK
• Employees: 6,347
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.49
• Shares Outstanding: 1,850,174,600
• 10 Day Avg. Volume: 27,263,329
• 30 Day Avg. Volume: 25,024,361
• PEG Ratio: -0.19
• Price to Book (P/B): 3.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.42
• Enterprise Value/Market Cap: 0.19
• Enterprise Value/Revenue: 0.76
• Enterprise Value/Gross Profit: 5.20
• Enterprise Value/Ebitda: -3.40
• 1Y Price Target: HK$13.26
• Price Target Upside: 54.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 51 Neutral
• Price Target: HK$8.50 ▼(-1.16%Downside)

The overall stock score for MicroPort Scientific is primarily impacted by its poor financial performance, characterized by operational inefficiencies and significant financial risk. While technical analysis provides some optimism with positive short-term trends, the negative valuation metrics highlight fundamental issues. The lack of earnings call insights and corporate events did not contribute to the score.

Positive Factors

Balance Sheet Management

MicroPort Scientific Corp had a cash and financial asset balance of US$981 million against short-term bank borrowings, showing strong balance sheet management.

Export Sales

Total export sales are expected to increase by 80%+ YoY to US$170 million.

Sales Growth

MicroPort Scientific Corp guides 10-11% overall sales growth for 2025, with cardiovascular segment expecting growth at 15%+.

Negative Factors

Net Loss Forecast

The company has widened its net loss forecasts for the upcoming years due to harsh price cuts from bulk purchases.

Price Cuts

The scope of price cuts has expanded to include innovative devices and small sales volume products.

Research and Development

R&D expenses are expected to be cut significantly, delaying the progress of products in development and reducing future sales growth potential.

MicroPort Scientific Business Overview & Revenue Model

Company Description

MicroPort Scientific Corporation (0853) is a global medical device company that focuses on the research, development, and manufacturing of a broad array of medical solutions. Headquartered in Shanghai, China, the company operates across various sectors, including cardiovascular, orthopedics, endovascular, neurovascular, and electrophysiology. MicroPort is dedicated to improving and extending patients' lives by providing innovative medical technologies and services.

How the Company Makes Money

MicroPort Scientific makes money primarily through the sale of its medical devices and solutions across its various sectors. The company's revenue streams include the direct sale of products such as stents, pacemakers, orthopedic implants, and other specialized medical devices to healthcare providers and distributors worldwide. Additionally, MicroPort engages in strategic partnerships and collaborations to enhance its product offerings and market reach, thereby contributing to its revenue. The company's earnings are also influenced by its investment in research and development, which drives innovation and the introduction of new products to the market.

MicroPort Scientific Financial Statement Overview

Summary

MicroPort Scientific faces considerable financial challenges characterized by persistent losses, high leverage, and cash flow issues. Despite revenue growth, the company's profitability and liquidity remain weak, necessitating strategic improvements in cost management and operational efficiency to stabilize its financial position.

Income Statement

The income statement shows significant challenges in profitability, with a negative net income and EBIT over the past three years. Although there has been a revenue growth trend from 2020 to 2024, the company has consistently reported negative EBIT and net profit margins, indicating persistent operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet highlights a concerning increase in total debt over the years, contributing to a high debt-to-equity ratio. Stockholders' equity has decreased significantly, reflecting financial instability. The equity ratio has also declined, indicating a heavier reliance on debt financing. These factors suggest potential solvency risks.

Cash Flow

The cash flow statement reveals negative operating cash flows, which paired with consistent negative free cash flows, indicates liquidity challenges. The company has been unable to generate positive cash flows from operations, relying heavily on financing activities to sustain operations, which poses a risk to financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03B	950.73M	840.83M	778.64M	648.73M
Gross Profit	574.09M	532.10M	501.77M	491.77M	436.03M
EBITDA	-45.30M	-382.54M	-430.26M	-251.29M	-106.87M
Net Income	-214.04M	-477.63M	-436.51M	-351.30M	-223.35M
Balance Sheet
Total Assets	3.63B	3.93B	3.99B	4.38B	2.47B
Cash, Cash Equivalents and Short-Term Investments	974.48M	1.13B	1.24B	1.75B	1.00B
Total Debt	1.69B	1.70B	1.47B	1.24B	296.31M
Total Liabilities	2.49B	2.53B	2.20B	2.16B	1.08B
Stockholders Equity	603.47M	757.82M	1.14B	1.49B	1.13B
Cash Flow
Free Cash Flow	-158.10M	-430.99M	-600.58M	-505.45M	-143.58M
Operating Cash Flow	-49.67M	-231.87M	-343.30M	-257.53M	-23.20M
Investing Cash Flow	-149.73M	-376.81M	-412.75M	-655.74M	-148.13M
Financing Cash Flow	-97.92M	434.90M	273.00M	1.66B	846.89M

MicroPort Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0853, the sentiment is Positive. The current price of 8.6 is above the 20-day moving average (MA) of 8.48, above the 50-day MA of 7.76, and above the 200-day MA of 7.03, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 55.22 is Neutral, neither overbought nor oversold. The STOCH value of 12.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0853.

MicroPort Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2172	72 Outperform	HK$7.07B	25.26	15.22%	1.82%	12.48%	71.75%
1858	65 Neutral	HK$6.98B	35.43	4.39%	0.84%	-32.05%	-54.47%
1302	65 Neutral	HK$7.60B	32.29	6.49%	―	0.87%	-18.05%
1789	62 Neutral	HK$6.22B	20.85	10.92%	1.30%	20.19%	45.54%
Sector *	59 Neutral	HK$15.54B	5.54	-7.44%	4.07%	11.55%	-28.15%
0853	51 Neutral	HK$15.91B	―	-31.45%	―	8.11%	55.55%
2252	46 Neutral	HK$16.09B	―	-160.49%	―	141.72%	38.39%

MicroPort Scientific Corporate Events

MicroPort Scientific Enhances Governance with New Nomination Committee

MicroPort Scientific Corporation has established a Nomination Committee as part of its governance structure, in accordance with the resolution of its Board of Directors. This move is aimed at enhancing the company’s corporate governance practices, potentially impacting its operational efficiency and stakeholder confidence.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort Scientific Announces Key Executive Appointments to Boost Global Strategy

MicroPort Scientific Corporation has announced the appointment of Mr. Jonathan W. Chen as the Rotating Co-chief Executive Officer, effective June 27, 2025. This strategic move is part of the company’s efforts to strengthen its internationalization and professionalization, as well as to develop a young management talent pipeline. Additionally, Dr. Brian Yale Chang has been appointed as the Chief Medical Officer, responsible for overseeing medical affairs strategies and providing expert medical insights across the company’s global operations. These appointments are expected to inject new momentum into MicroPort’s strategic execution and sustainable growth, enhancing its operational capabilities and expanding its global presence.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort Scientific Secures Shareholder Approval for Key Resolutions at AGM

MicroPort Scientific Corporation announced that all proposed resolutions at its Annual General Meeting on May 30, 2025, were approved by shareholders. Key resolutions included the re-election of directors, authorization of director remuneration, reappointment of KPMG as auditor, and granting mandates for share buybacks and issuance. This successful AGM reflects strong shareholder support, potentially enhancing the company’s governance and operational strategies.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort Scientific Announces Strategic Share Sale of Shanghai MedBot

MicroPort Scientific’s subsidiary, Shanghai Latent, has entered into a Block Trade Agreement to sell up to 3% of Shanghai MedBot’s issued share capital through placing agents. This transaction, alongside a simultaneous placing agreement by Shanghai MedBot, involves a significant discount on the sale price compared to recent market prices, indicating a strategic move to adjust its financial positioning without creating a new substantial shareholder.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort’s Endovastec Reports Q1 2025 Financial Results

Shanghai MicroPort Endovascular MedTech, a subsidiary of MicroPort Scientific, reported a decline in revenue and profit for the first quarter of 2025 compared to the same period in 2024. Despite the decrease in financial performance, the company’s total assets and equity showed slight growth, indicating a stable financial position amid challenging market conditions.

MicroPort Scientific Announces 2025 Annual General Meeting and Key Resolutions

MicroPort Scientific Corporation has announced its Annual General Meeting scheduled for May 30, 2025, in Shanghai, China. Key resolutions include the re-election of directors, approval of financial statements, and granting mandates for share buybacks and issuance. These actions are significant for maintaining the company’s governance and operational flexibility, potentially impacting its market positioning and shareholder value.